| Identifiers | |
|---|---|
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C23H29ClN6O3 |
| Molar mass | 472.97 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
LBP-1 is a drug originally developed byOrganon for the treatment ofneuropathic pain,[1][2][3] It acts as a potent and selectivecannabinoidreceptoragonist, with high potency at both theCB1 andCB2 receptors, but low penetration of theblood–brain barrier. This makes LBP-1 peripherally selective, and while it was effective in animal models of neuropathic pain andallodynia, it did not produce cannabinoid-appropriate responding suggestive of central effects, at any dose tested.[4]